

Cervical Cancer – Friday 27 November 2020

2pm – 4.45pm (AEDT)

Time	Session	Presenter
2.00 pm	WELCOME INTRODUCTION	Michelle Harrison
2.05pm	Session 1: Early cancer pathology / surgery Pathology Delgado 1990 (1) Surgery vs radiotherapy Landoni 1997 and 2017 (2, 3) Minimally invasive surgery vs open surgery LACC, Ramirez 2018 (4) Sentinel node Balaya (5) Fertility Sparing Bentivegna 2016 Systematic rv (6)	Kristen Moloney Rhett Morton Rhett Morton Nicole Krzys Nisha Jagasia
2.45pm	SUMMARY & DISCUSSION	
2.50pm	Session 2: Adjuvant RT and ChemoRT Intermediate risk GOG 092, Sedlis 1999+Rotman 2006 (7, 8) High risk - Concurrent ChemoRT vs RT alone GOG 0109, Peters 2000 (9) MA 2008 (10) Brachytherapy Potter 2011 (11), RetroEmbrace, Sturdza 2016 (12)	Carmen Swanton Sarah Leeson Girish Shah Krystel Tran
3.25pm	SUMMARY & DISCUSSION	
3.30pm	Break	
3.35pm	Session 3: Neoadjuvant/ adjuvant chemotherapy Neoadjuvant Chemo+Surgery vs Surgery Meta-Analysis 2003 (13) Neoadjuvant Chemo+Surgery vs Radiotherapy Gupta 2018 (14) Adjuvant Chemotherapy Duenas-Gonzales 2011 (15)	Michael Krasovitsky Alice Minninnick Fiona Paxton-Hall
4.05pm	SUMMARY & DISCUSSION	
4.10pm	Session 4: Advanced disease Doublet chemotherapy: GOG, Monk 2009 (16) Bevacizumab Tewari 2014 (17) + update 2017 (18)	Shweta Srinivasa Po Yee Yip
4.30pm	SUMMARY & DISCUSSION	
4.35pm	Closing Remarks	Michelle Harrison & Peey Sei Kok

Program correct at time of publishing. Subject to change without notice 25/11/2020

Vulval Cancer Preceptorship – Saturday 28 November 2020

10am – 12pm (AEDT)

Time	Session	Presenter
10.00am	WELCOME & INTRODUCTION	Michelle Harrison
10.05am	Session 5: Early cancer <u>Predictive/Prognostic Pathology</u> AGO-CARE1, Klapdor 2019 (19) + GRIONSS V-1, Oonk 2010 (20) <u>Sentinel node</u> Levenbeck (21)+ GROINS V (22) <u>Groin RT vs Surgery</u> Stehman 1992 (23) <u>Margins</u> Heaps 1990 (24) + Te Grootenhuys 2019 (25)	Melissa McGauran Huan (Echo) Xie Nisha Jagasia Rosemary McBain
10.40am	SUMMARY & DISCUSSION	
10.45am	BREAK	
10.50am	Session 6: Adjuvant therapy <u>Adjuvant RT for +ve margin</u> Bedell 2019 (26)+ Viswanathan 2013 (27) <u>Adjuvant Groin RT for +ve nodes</u> Parthasarathy 2006 (28) Homesley 1986 (29)+ AGO-Care1, Mahner 2015 (30) <u>ChemoRT</u> Rydzewski 2018 (31)	April Xu-Holland Caitlin Murphy Tiffany Daly Avraham Travers
11.25am	SUMMARY & DISCUSSION	
11.30am	Session 7: Locally advanced <u>NA CRT + Surgery</u> GOG 205, Moore 2012 (32) <u>Primary CRT</u> Rao 2017 (33)	Kate Wilkinson Po Yee Yip
11.50am	SUMMARY & DISCUSSION	
11.55am	CLOSING REMARKS	Michelle Harrison & Peey-Sei Kok

Program correct at time of publishing. Subject to change without notice 23/10/2020

PAPERS

1. Delgado G, Bundy B, Zaino R, Sevin BU, Creasman WT, Major F. Prospective surgical-pathological study of disease-free interval in patients with stage IB squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study. *Gynecologic oncology*. 1990;38(3):352-7.
2. Landoni F, Maneo A, Colombo A, Placa F, Milani R, Perego P, et al. Randomised study of radical surgery versus radiotherapy for stage Ib-IIa cervical cancer. *Lancet (London, England)*. 1997;350(9077):535-40.
3. Landoni F, Colombo A, Milani R, Placa F, Zanagnolo V, Mangioni C. Randomized study between radical surgery and radiotherapy for the treatment of stage IB-IIA cervical cancer: 20-year update. *Journal of gynecologic oncology*. 2017;28(3):e34.
4. Ramirez PT, Frumovitz M, Pareja R, Lopez A, Vieira M, Ribeiro R, et al. Minimally Invasive versus Abdominal Radical Hysterectomy for Cervical Cancer. *New England Journal of Medicine*. 2018;379(20):1895-904.
5. Balaya V, Lécuru F, Magaud L, Ngô C, Huchon C, Bats A-S, et al. Perioperative morbidity of radical trachelectomy with lymphadenectomy in early-stage cervical cancer: a French prospective multicentric cohort. *Journal of gynecologic oncology*. 2019;30(3).
6. Bentivegna E, Gouy S, Maulard A, Chargari C, Leary A, Morice P. Oncological outcomes after fertility-sparing surgery for cervical cancer: a systematic review. *The Lancet Oncology*. 2016;17(6):e240-e53.
7. Sedlis A, Bundy BN, Rotman MZ, Lentz SS, Muderspach LI, Zaino RJ. A randomized trial of pelvic radiation therapy versus no further therapy in selected patients with stage IB carcinoma of the cervix after radical hysterectomy and pelvic lymphadenectomy: A Gynecologic Oncology Group Study. *Gynecologic oncology*. 1999;73(2):177-83.
8. Rotman M, Sedlis A, Piedmonte MR, Bundy B, Lentz SS, Muderspach LI, et al. A phase III randomized trial of postoperative pelvic irradiation in Stage IB cervical carcinoma with poor prognostic features: follow-up of a gynecologic oncology group study. *International journal of radiation oncology, biology, physics*. 2006;65(1):169-76.
9. Peters WA, 3rd, Liu PY, Barrett RJ, 2nd, Stock RJ, Monk BJ, Berek JS, et al. Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervix. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*. 2000;18(8):1606-13.
10. Reducing uncertainties about the effects of chemoradiotherapy for cervical cancer: a systematic review and meta-analysis of individual patient data from 18 randomized trials. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*. 2008;26(35):5802-12.
11. Potter R, Georg P, Dimopoulos JC, Grimm M, Berger D, Nesvacil N, et al. Clinical outcome of protocol based image (MRI) guided adaptive brachytherapy combined with 3D conformal radiotherapy with or without chemotherapy in patients with locally advanced cervical cancer. *Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology*. 2011;100(1):116-23.
12. Sturdza A, Potter R, Fokdal LU, Haie-Meder C, Tan LT, Mazon R, et al. Image guided brachytherapy in locally advanced cervical cancer: Improved pelvic control and survival in RetroEMBRACE, a multicenter cohort study. *Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology*. 2016;120(3):428-33.
13. Neoadjuvant chemotherapy for locally advanced cervical cancer: a systematic review and meta-analysis of individual patient data from 21 randomised trials. *Eur J Cancer*. 2003;39(17):2470-86.
14. Gupta S, Maheshwari A, Parab P, Mahantshetty U, Hawaldar R, Sastri Chopra S, et al. Neoadjuvant Chemotherapy Followed by Radical Surgery Versus Concomitant Chemotherapy and Radiotherapy in Patients With Stage IB2, IIA, or IIB Squamous Cervical Cancer: A Randomized Controlled Trial. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*. 2018;36(16):1548-55.
15. Duenas-Gonzalez A, Zarba JJ, Patel F, Alcedo JC, Beslija S, Casanova L, et al. Phase III, open-label, randomized study comparing concurrent gemcitabine plus cisplatin and radiation followed by adjuvant gemcitabine and cisplatin versus concurrent cisplatin and radiation in patients with stage IIB to IVA carcinoma of the cervix. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*. 2011;29(13):1678-85.

16. Monk BJ, Sill MW, McMeekin DS, Cohn DE, Ramondetta LM, Boardman CH, et al. Phase III trial of four cisplatin-containing doublet combinations in stage IVB, recurrent, or persistent cervical carcinoma: a Gynecologic Oncology Group study. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*. 2009;27(28):4649-55.
17. Tewari KS, Sill MW, Long HJ, 3rd, Penson RT, Huang H, Ramondetta LM, et al. Improved survival with bevacizumab in advanced cervical cancer. *The New England journal of medicine*. 2014;370(8):734-43.
18. Tewari KS, Sill MW, Penson RT, Huang H, Ramondetta LM, Landrum LM, et al. Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic Oncology Group 240). *Lancet (London, England)*. 2017;390(10103):1654-63.
19. Klapdor R, Wolber L, Hanker L, Schmalfeldt B, Canzler U, Fehm T, et al. Predictive factors for lymph node metastases in vulvar cancer. An analysis of the AGO-CaRE-1 multicenter study. *Gynecologic oncology*. 2019;154(3):565-70.
20. Oonk MH, van Hemel BM, Hollema H, de Hullu JA, Ansink AC, Vergote I, et al. Size of sentinel-node metastasis and chances of non-sentinel-node involvement and survival in early stage vulvar cancer: results from GROINSS-V, a multicentre observational study. *The Lancet Oncology*. 2010;11(7):646-52.
21. Levenback CF, Ali S, Coleman RL, Gold MA, Fowler JM, Judson PL, et al. Lymphatic mapping and sentinel lymph node biopsy in women with squamous cell carcinoma of the vulva: a gynecologic oncology group study. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*. 2012;30(31):3786-91.
22. Te Grootenhuys NC, van der Zee AG, van Doorn HC, van der Velden J, Vergote I, Zanagnolo V, et al. Sentinel nodes in vulvar cancer: Long-term follow-up of the GROningen INternational Study on Sentinel nodes in Vulvar cancer (GROINSS-V) I. *Gynecologic oncology*. 2016;140(1):8-14.
23. Stehman FB, Bundy BN, Thomas G, Varia M, Okagaki T, Roberts J, et al. Groin dissection versus groin radiation in carcinoma of the vulva: a Gynecologic Oncology Group study. *International journal of radiation oncology, biology, physics*. 1992;24(2):389-96.
24. Heaps JM, Fu YS, Montz FJ, Hacker NF, Berek JS. Surgical-pathologic variables predictive of local recurrence in squamous cell carcinoma of the vulva. *Gynecologic oncology*. 1990;38(3):309-14.
25. Te Grootenhuys NC, Pouwer AW, de Bock GH, Hollema H, Bulten J, van der Zee AGJ, et al. Margin status revisited in vulvar squamous cell carcinoma. *Gynecologic oncology*. 2019;154(2):266-75.
26. Bedell SM, Hedberg C, Griffin A, Pearson H, Wilhite A, Rubin N, et al. Role of adjuvant radiation or re-excision for early stage vulvar squamous cell carcinoma with positive or close surgical margins. *Gynecologic oncology*. 2019;154(2):276-9.
27. Viswanathan AN, Pinto AP, Schultz D, Berkowitz R, Crum CP. Relationship of margin status and radiation dose to recurrence in post-operative vulvar carcinoma. *Gynecologic oncology*. 2013;130(3):545-9.
28. Parthasarathy A, Cheung MK, Osann K, Husain A, Teng NN, Berek JS, et al. The benefit of adjuvant radiation therapy in single-node-positive squamous cell vulvar carcinoma. *Gynecologic oncology*. 2006;103(3):1095-9.
29. Homesley HD, Bundy BN, Sedlis A, Adcock L. Radiation therapy versus pelvic node resection for carcinoma of the vulva with positive groin nodes. *Obstet Gynecol*. 1986;68(6):733-40.
30. Mahner S, Jueckstock J, Hilpert F, Neuser P, Harter P, de Gregorio N, et al. Adjuvant Therapy in Lymph Node-Positive Vulvar Cancer: The AGO-CaRE-1 Study. *JNCI: Journal of the National Cancer Institute*. 2015;107(3).
31. Rydzewski NR, Kanis MJ, Donnelly ED, Lurain JR, Strauss JB. Role of adjuvant external beam radiotherapy and chemotherapy in one versus two or more node-positive vulvar cancer: A National Cancer Database study. *Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology*. 2018;129(3):534-9.
32. Moore DH, Thomas GM, Montana GS, Saxer A, Gallup DG, Olt G. Preoperative chemoradiation for advanced vulvar cancer: a phase II study of the Gynecologic Oncology Group. *International journal of radiation oncology, biology, physics*. 1998;42(1):79-85.
33. Rao YJ, Chin RI, Hui C, Mutch DG, Powell MA, Schwarz JK, et al. Improved survival with definitive chemoradiation compared to definitive radiation alone in squamous cell carcinoma of the vulva: A review of the National Cancer Database. *Gynecologic oncology*. 2017;146(3):572-9.